Renin inhibitors.

Area of Science:

• Cardiovascular pharmacology
• Nephrology
• Hypertension management

Background:

• Aliskiren is the only US FDA-approved oral renin inhibitor for hypertension.
• It demonstrates efficacy in lowering blood pressure, both as monotherapy and in combination with other antihypertensives.

Purpose of the Study:

• To summarize key points and practical recommendations for aliskiren use.
• To highlight its role in hypertension management and potential benefits in specific patient populations.

Main Methods:

• Review of clinical data and evidence regarding aliskiren's efficacy and safety.
• Analysis of its pharmacokinetic profile and interactions with other antihypertensive agents.

Main Results:

• Aliskiren offers comparable blood pressure reduction to other agents.
• Early data suggest benefits in diabetic nephropathy, with cardiovascular outcomes yet to be determined.
• No initial dose adjustment is needed for elderly or renally impaired patients, though caution is advised in severe impairment or renal artery stenosis.
• Combining aliskiren with agents that increase plasma renin activity, like thiazide diuretics, ACE inhibitors, and ARBs, is considered rational.
• A reactive rise in renin occurs with aliskiren, but it is not evidenced as harmful.
• Adverse events like edema and cough are reported at low rates, comparable to or lower than other agents.

Conclusions:

• Aliskiren is an effective oral renin inhibitor for hypertension.
• Its role in diabetic nephropathy warrants further investigation for cardiovascular benefits.
• Clinical experience guides its use in specific patient groups and in combination therapy.